Skip Navigation

Bruce E. Johnson, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chief Clinical Research Officer
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Genomic characterization
  • Mesothelioma
  • Non-small cell lung cancer
  • Small cell lung cancer

Contact Information

  • Appointments877-332-4294 (new)
    617-632-6190 (established)
  • Office Phone Number617-632-4790
  • Fax617-632-5786

Bio

Dr. Johnson received his MD from the University of Minnesota in 1979 and his postgraduate training at the University of Chicago and the National Cancer Institute. After serving at NCI, where he most recently headed the Lung Cancer Biology Section, he joined DFCI in 1999. He currently leads the Dana-Farber/Harvard Cancer Center Lung Cancer Program and is the Chief Clinical Research Officer at the Dana-Farber Cancer Institute.

Board Certification:

  • Internal Medicine, 1982
  • Medical Oncology, 1985

Fellowship:

  • National Cancer Institute, Medicine

Residency:

  • University of Chicago Hospitals and Clinics, Internal Medicine

Medical School:

  • University of Minnesota, Minneapolis School of Medicine

Recent Awards:

  • The ASCO Cancer Foundation Translational Research Professorship 2008-2013
  • Member of the Association of American Physicians 2015
  • Fellow of the American Society of Clinical Oncology 2012
  • American Association for Cancer Research Team Science Award 2010
  • International Association for Study of Lung Cancer Scientific Award 2009

Research

The impact of genomic changes on the targeted treatment of thoracic malignancies

 My research is based on my multiple responsibilities as the leader of the Lung Cancer Program at the Harvard Medical School affiliated institutions. In my past role as Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, I have been responsible for fostering collaborative research across the clinical disciplines, integrating population and basic science into our research programs, and applying innovative therapeutic strategies into the treatment of our patients with lung cancer. I have led the Lung Cancer Program within the Dana-Farber/Harvard Cancer Center from a Program in Development to a full Program and was part of the successful Dana-Farber/ Harvard Cancer Center Grant competitive renewal in 2011 and received an exceptional rating. Under my leadership, the Lung Cancer Program has been able to increase its NIH funding 5 fold in the last 16 years. In addition, the Dana-Farber/Harvard Cancer Center Lung Cancer Program successfully renewed the Lung Cancer Specialized Program of Research Excellence Grant (SPORE) in 2008 and will submit the application in the fall 2016.   My translational research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies with specific genomic changes. I provide care in our Center for patients with thoracic malignancies one day per week. I also lecture widely on my research and treatment of patients with lung cancer.

Members of our research group identified the link between mutations of the epidermal growth factor receptor and response to the epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib and erlotinib. Subsequent research has now changed the paradigm of treatment for patients with non-small cell lung cancer and sensitizing mutations of the epidermal growth factor receptor so the standard of care around the world is to get treated with erlotinib or gefitinib rather than chemotherapy. I am one of the patent holders of the test and now more than 50% of all the patients with nonsquamous non-small cell lung cancer get the test.  

The systematic characterization of the genomic changes in lung cancer has now identified multiple changes that can lead to treatment with approved targeted agents (gefitinib and erlotinib) or enrollment onto ongoing investigation studies. These include EGFR, KRAS, HER2, BRAF, and PIK3CA mutations as well as the ALK and ROS1 rearrangements. I worked with members of our research group to set up systematic genomic characterization of nearly all of our advanced non-small cell lung cancer patients for EGFR, KRAS, HER2, BRAF, PI3KA mutations, ALK and ROS1 rearrangements, plus HER2 and MET amplification. We now characterize these genomic changes in 30-50 patients per month, track the results, are working toward placing them in the medical record, and preferentially steering these patients into appropriate genomically based protocols. It is our goal to treat a quarter of our patients with non-small cell lung cancer with targeted agents.

Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. Cancer Res. 2021 Mar 02.
View in: PubMed

Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021 03; 53(3):332-341.
View in: PubMed

Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems. Science. 2021 01 29; 371(6528).
View in: PubMed

Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 Feb 15; 27(4):1105-1118.
View in: PubMed

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2020 Sep 22.
View in: PubMed

Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. JCO Clin Cancer Inform. 2020 08; 4:680-690.
View in: PubMed

Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307.
View in: PubMed

A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 08; 26(8):1271-1279.
View in: PubMed

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802.
View in: PubMed

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell. 2020 04 16; 181(2):236-249.
View in: PubMed

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377.
View in: PubMed

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. J Thorac Imaging. 2020 Mar; 35(2):101-107.
View in: PubMed

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. Eur J Radiol Open. 2020; 7:100210.
View in: PubMed

The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer. Radiat Oncol. 2020 Jan 14; 15(1):14.
View in: PubMed

From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 05.
View in: PubMed

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
View in: PubMed

Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncol. 2019 Jul 25.
View in: PubMed

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019 09; 14(9):1666-1671.
View in: PubMed

Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):431-434.
View in: PubMed

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. Eur J Radiol Open. 2019; 6:128-131.
View in: PubMed

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87.
View in: PubMed

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019 05; 14(5):876-889.
View in: PubMed

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 04 01; 37(10):834-849.
View in: PubMed

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. Oncologist. 2019 08; 24(8):e749-e754.
View in: PubMed

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 02; 128:74-90.
View in: PubMed

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
View in: PubMed

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. Eur J Radiol. 2018 Dec; 109:68-76.
View in: PubMed

Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy. J Surg Oncol. 2018 Dec; 118(7):1170-1177.
View in: PubMed

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):158-165.
View in: PubMed

2018 ASCO Presidential Address: "Delivering Discoveries: Expanding the Reach of Precision Medicine". J Clin Oncol. 2018 10 10; 36(29):2899-2903.
View in: PubMed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
View in: PubMed

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. J Thorac Oncol. 2018 09; 13(9):1400-1409.
View in: PubMed

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. Arch Pathol Lab Med. 2018 07; 142(7):796-797.
View in: PubMed

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047.
View in: PubMed

Expanding the Reach of Targeted Therapy in Lung Cancer. Ann Oncol. 2017 Oct; 28 Suppl 9:ix5.
View in: PubMed

Training oncologists to carry out clinical trials. Ann Oncol. 2017 Oct; 28 Suppl 9:ix1.
View in: PubMed

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 10; 18(10):1307-1316.
View in: PubMed

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017 Nov 01; 123(21):4099-4105.
View in: PubMed

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130.
View in: PubMed

Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. Eur J Radiol. 2017 Mar; 88:15-20.
View in: PubMed

Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
View in: PubMed

Divide and Conquer to Treat Lung Cancer. N Engl J Med. 2016 11 10; 375(19):1892-1893.
View in: PubMed

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA Oncol. 2016 Sep 01; 2(9):1240-2.
View in: PubMed

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res. 2017 Jan 01; 23(1):204-213.
View in: PubMed

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020.
View in: PubMed

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul; 17(7):984-993.
View in: PubMed

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 05; 17(5):642-50.
View in: PubMed

Clinical trial enrollment expansion to the community. J Clin Oncol. 2016 Mar; 34(7_suppl):112.
View in: PubMed

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501.
View in: PubMed

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar; 23(3):329-36.
View in: PubMed

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr; 11(4):556-65.
View in: PubMed

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2016 Mar 01; 122(5):766-72.
View in: PubMed

Emerging gene mutation targets in lung cancer. Clin Adv Hematol Oncol. 2015 Dec; 13(12):812-4.
View in: PubMed

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res. 2016 Apr 15; 22(8):1940-50.
View in: PubMed

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res. 2016 Mar 01; 22(5):1103-10.
View in: PubMed

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in: PubMed

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-777.
View in: PubMed

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7.
View in: PubMed

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 2015 Feb 28; 6(6):4527-36.
View in: PubMed

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015 May; 84(5):998-1004.
View in: PubMed

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015 Feb 01; 121(3):448-56.
View in: PubMed

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). J Thorac Oncol. 2014 Sep; 9(9):1411-7.
View in: PubMed

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014 Nov; 86(2):241-6.
View in: PubMed

Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst. 2014 Aug; 106(8).
View in: PubMed

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. J Natl Cancer Inst. 2014 Jul; 106(7).
View in: PubMed

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):880-7.
View in: PubMed

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006.
View in: PubMed

State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology. 2014 Apr; 271(1):6-27.
View in: PubMed

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov; 8(11):1434-7.
View in: PubMed

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 01; 31(31):3926-34.
View in: PubMed

The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med. 2013 Oct 01; 188(7):770-5.
View in: PubMed

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15; 73(22):6770-9.
View in: PubMed

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013 Nov 01; 119(21):3761-8.
View in: PubMed

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013 Aug; 8(8):1059-68.
View in: PubMed

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013 Aug 15; 19(16):4532-40.
View in: PubMed

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol. 2013 Jul; 201(1):W64-71.
View in: PubMed

Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts. J Natl Cancer Inst. 2013 May 01; 105(9):589-90.
View in: PubMed

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer. 2013 Jun 01; 119(11):2048-60.
View in: PubMed

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84.
View in: PubMed

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar; 79(3):283-8.
View in: PubMed

The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1767-1774.
View in: PubMed

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1594-601.
View in: PubMed

ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. Ann Intern Med. 2012 Sep 18; 157(6):JC3-4.
View in: PubMed

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20.
View in: PubMed

Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25.
View in: PubMed

Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer. 2012 Nov; 78(2):161-6.
View in: PubMed

Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal. 2012 Jul; 32 Suppl 1:S117-24.
View in: PubMed

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging. 2012 Jun 29; 12:225-35.
View in: PubMed

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012 Aug 15; 18(16):4406-14.
View in: PubMed

Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012 Sep; 144(3):S39-42.
View in: PubMed

Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res. 2012 Feb 01; 18(3):619-24.
View in: PubMed

A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension. Am J Cardiol. 2012 Apr 01; 109(7):1066-72.
View in: PubMed

Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung Cancer. 2012 May; 76(2):144-9.
View in: PubMed

Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011 Nov; 6(11):1841-8.
View in: PubMed

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89.
View in: PubMed

The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
View in: PubMed

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb; 6(2):244-85.
View in: PubMed

Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36.
View in: PubMed

Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jul 01; 117(13):2961-9.
View in: PubMed

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62.
View in: PubMed

Submaximal exercise gas exchange is an important prognostic tool to predict adverse outcomes in heart failure. Eur J Heart Fail. 2011 Mar; 13(3):303-10.
View in: PubMed

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010 Dec 01; 16(23):5873-82.
View in: PubMed

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8.
View in: PubMed

Virginia Tech Carilion School of Medicine and Research Institute. Acad Med. 2010 Sep; 85(9 Suppl):S582-5.
View in: PubMed

Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women. Lung Cancer. 2011 Mar; 71(3):258-63.
View in: PubMed

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010 Jul; 11(7):619-26.
View in: PubMed

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010 Mar 01; 16(5):1561-71.
View in: PubMed

ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal women. Ann Intern Med. 2010 Feb 16; 152(4):JC-28.
View in: PubMed

Parity and risk of lung cancer in women. Am J Epidemiol. 2010 Mar 01; 171(5):557-63.
View in: PubMed

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7502-7509.
View in: PubMed

The Intermountain Risk Score, based on common laboratory tests, was highly predictive of short-term mortality. Evid Based Med. 2009 Dec; 14(6):186.
View in: PubMed

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):193-201.
View in: PubMed

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):357-60.
View in: PubMed

Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer. 2009 Sep 15; 115(18):4156-66.
View in: PubMed

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1156-62.
View in: PubMed

Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res. 2009 Sep 01; 15(17):5317-22.
View in: PubMed

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23.
View in: PubMed

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009 Aug 15; 15(16):5267-73.
View in: PubMed

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009 Aug; 13(8B):1977-86.
View in: PubMed

Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):405-11.
View in: PubMed

ACP Journal Club. Postmenopausal hormone therapy was cost-effective when started at age 50 years but not at 65 years. Ann Intern Med. 2009 Jun 16; 150(12):JC6-15.
View in: PubMed

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009 May 15; 15(10):3484-94.
View in: PubMed

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009 May 15; 15(10):3600-9.
View in: PubMed

Predictive value of heart rate recovery and peak oxygen consumption for long-term mortality in patients with coronary heart disease. Am J Cardiol. 2009 Jun 15; 103(12):1641-6.
View in: PubMed

A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009 Feb; 137(2):453-8.
View in: PubMed

Impact of graft volume reduction for oversized grafts after lung transplantation on outcome in recipients with end-stage restrictive pulmonary diseases. J Heart Lung Transplant. 2009 Feb; 28(2):130-4.
View in: PubMed

Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer. 2008 Dec 15; 113(12):3440-9.
View in: PubMed

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73.
View in: PubMed

Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75.
View in: PubMed

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15.
View in: PubMed

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008 Oct 15; 113(8):2129-38.
View in: PubMed

Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg. 2008 Oct; 86(4):1116-22.
View in: PubMed

Heart rate recovery and prognosis in heart failure patients. Eur J Appl Physiol. 2009 Jan; 105(1):37-45.
View in: PubMed

Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5.
View in: PubMed

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14.
View in: PubMed

Long-term mortality with multiple treadmill exercise test abnormalities: comparison between patients with and without cardiovascular disease. Am Heart J. 2008 Oct; 156(4):783-9.
View in: PubMed

Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology. 2008 Jul; 248(1):278-87.
View in: PubMed

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20; 26(15):2442-9.
View in: PubMed

Preoperative evaluation of the gynecologic patient: considerations for improved outcomes. Obstet Gynecol. 2008 May; 111(5):1183-94.
View in: PubMed

Leptin, a novel predictor of lung function in heart failure. Chest. 2008 Aug; 134(2):346-350.
View in: PubMed

Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release. Physiol Genomics. 2008 May 13; 33(3):323-32.
View in: PubMed

Small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar; 6(3):294-314.
View in: PubMed

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008 Feb 20; 26(6):983-94.
View in: PubMed

Civic norms and etiquettes regarding marijuana use in public settings in New York City. Subst Use Misuse. 2008; 43(7):895-918.
View in: PubMed

Family medicine practice in rural any-country. Fam Med. 2008 Jan; 40(1):55-6.
View in: PubMed

Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
View in: PubMed

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6175-81.
View in: PubMed

Right ventricular function with hypoxic exercise: effects of sildenafil. Eur J Appl Physiol. 2007 Dec; 102(1):87-95.
View in: PubMed

A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis. Evid Based Med. 2007 Oct; 12(5):145.
View in: PubMed

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007 Sep 20; 25(27):4270-7.
View in: PubMed

A once-yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis. ACP J Club. 2007 Sep-Oct; 147(2):31.
View in: PubMed

LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16; 448(7155):807-10.
View in: PubMed

Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4583-8.
View in: PubMed

Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4628-31.
View in: PubMed

Herbal supplements did not relieve vasomotor symptoms of menopause in women. Evid Based Med. 2007 Jun; 12(3):78.
View in: PubMed

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15; 67(10):4933-9.
View in: PubMed

Herbal supplements did not relieve vasomotor symptoms of menopause. ACP J Club. 2007 May-Jun; 146(3):65.
View in: PubMed

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43.
View in: PubMed

Pulmonary function changes associated with cardiomegaly in chronic heart failure. J Card Fail. 2007 Mar; 13(2):100-7.
View in: PubMed

Arginine 16 glycine beta2-adrenoceptor polymorphism and cardiovascular structure and function in patients with heart failure. J Am Soc Echocardiogr. 2007 Mar; 20(3):290-7.
View in: PubMed

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. 2007 Mar 01; 109(5):924-32.
View in: PubMed

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6.
View in: PubMed

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8.
View in: PubMed

Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S13-9.
View in: PubMed

Beta2-adrenergic receptor genotype and pulmonary function in patients with heart failure. Chest. 2006 Nov; 130(5):1527-34.
View in: PubMed

Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S8-12.
View in: PubMed

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20.
View in: PubMed

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706.
View in: PubMed

Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4436s-4440s.
View in: PubMed

Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s.
View in: PubMed

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
View in: PubMed

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4416s-4420s.
View in: PubMed

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.
View in: PubMed

Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul; 4(6):602-22.
View in: PubMed

Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw. 2006 Jul; 4(6):631-8.
View in: PubMed

Oestrogen did not improve health related quality of life in postmenopausal women with hysterectomy. Evid Based Med. 2006 Jun; 11(3):76.
View in: PubMed

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95.
View in: PubMed

The Arg16Gly polymorphism of the beta2-adrenergic receptor and the natriuretic response to rapid saline infusion in humans. J Physiol. 2006 Aug 01; 574(Pt 3):947-54.
View in: PubMed

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):751-8.
View in: PubMed

A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):888-96.
View in: PubMed

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205.
View in: PubMed

Left atrial index is a predictor of exercise capacity in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2005 Dec; 18(12):1373-80.
View in: PubMed

Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 2005 Nov 15; 11(22):8122-30.
View in: PubMed

Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2005 Nov; 3 Suppl 1:S17-21.
View in: PubMed

The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. Chest. 2005 Nov; 128(5):3261-8.
View in: PubMed

Small-cell lung cancer. Lancet. 2005 Oct 15-21; 366(9494):1385-96.
View in: PubMed

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? J Clin Oncol. 2005 Oct 01; 23(28):6813-6.
View in: PubMed

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005 Sep 01; 65(17):7525-9.
View in: PubMed

Statistic on life expectancy challenged. Postgrad Med. 2005 Sep; 118(3):1; author reply 1-2.
View in: PubMed

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005 Aug 17; 97(16):1185-94.
View in: PubMed

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg. 2005 Aug; 130(2):528-37.
View in: PubMed

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 01; 23(25):5892-9.
View in: PubMed

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 01; 23(25):5900-9.
View in: PubMed

Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology. 2005; 68(4-6):500-10.
View in: PubMed

Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s.
View in: PubMed

Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5022s-5026s.
View in: PubMed

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol. 2005 Aug 01; 23(22):5099-107.
View in: PubMed

Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure. J Card Fail. 2005 Jun; 11(5):333-9.
View in: PubMed

Sunburn and swelling: the edema of erythema. South Med J. 2005 Jun; 98(6):672.
View in: PubMed

Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005 May 10; 23(14):3279-87.
View in: PubMed

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005 May 10; 23(14):3227-34.
View in: PubMed

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3417-24.
View in: PubMed

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005 May 01; 11(9):3514-22.
View in: PubMed

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005 Apr 15; 11(8):2785-808.
View in: PubMed

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92.
View in: PubMed

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3788-93.
View in: PubMed

Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004 Nov 02; 44(9):1819-24.
View in: PubMed

Review: prophylactic use of Vitamin D reduces falls in older persons. ACP J Club. 2004 Nov-Dec; 141(3):66.
View in: PubMed

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004 Oct 15; 64(20):7241-4.
View in: PubMed

Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s.
View in: PubMed

Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4254s-4257s.
View in: PubMed

Imatinib for small cell lung cancer, aiming for a target in vivo. Clin Cancer Res. 2004 May 15; 10(10):3235-6.
View in: PubMed

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004 May; 44(2):221-30.
View in: PubMed

Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004 May; 44(2):213-20.
View in: PubMed

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500.
View in: PubMed

High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 2004 Apr 08; 23(15):2716-26.
View in: PubMed

Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):309-22.
View in: PubMed

Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1098-105.
View in: PubMed

Dietary supplements containing red clover extracts were no better than placebo for hot flashes in menopause. ACP J Club. 2004 Mar-Apr; 140(2):47.
View in: PubMed

Socioeconomic marginality and health services utilization among Central Harlem substance users. Subst Use Misuse. 2004 Jan; 39(1):61-85.
View in: PubMed

Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5880-7.
View in: PubMed

Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5915-21.
View in: PubMed

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
View in: PubMed

Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning. J Natl Cancer Inst. 2003 Oct 01; 95(19):1422-4.
View in: PubMed

Imatinib in small cell lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S49-53.
View in: PubMed

Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer. 2003 Jul 01; 98(1):135-43.
View in: PubMed

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res. 2003 May; 9(5):1698-704.
View in: PubMed

A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2003 Mar; 9(3):917-22.
View in: PubMed

Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology. 2003; 64(4):399-406.
View in: PubMed

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002 Nov 01; 62(21):6304-11.
View in: PubMed

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer. 2002 Oct 01; 95(7):1528-38.
View in: PubMed

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7.
View in: PubMed

Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer. Am J Clin Oncol. 2002 Jun; 25(3):269-73.
View in: PubMed

Management of small cell lung cancer. Clin Chest Med. 2002 Mar; 23(1):225-39.
View in: PubMed

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):620-7.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1234
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Ratings

Top